XML 42 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

During the quarter ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities set forth in the table below.

 

Type of Trading Arrangement

Name and Position

Action

Adoption/ Termination

Date

Rule 10b5-1*

Non-

Rule 10b5-1**

Total Shares of Class A Common Stock to be Sold

Expiration Date

Celia Lin, Chief Medical Officer***

Adoption

October 10, 2023

X

Up to 134,401

December 19, 2024****

* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.

***Dr. Lin separated from Vera effective January 3, 2024.

****In connection with her separation from Vera, Dr. Lin terminated this 10b5-1 Plan effective January 19, 2024.
Celia Lin [Member]  
Trading Arrangements, by Individual  
Name Celia Lin
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Non-Rule 10b5-1 Arrangement Adopted false
Adoption Date October 10, 2023
Termination Date January 19, 2024
Arrangement Duration 436 days
Aggregate Available 134,401
Expiration Date December 19, 2024